Biosciences at Brighton

University of Brighton biosciences blog

Photo of surgery

Nanoparticle research may improve tumour treatment

Researchers, coordinated by a Brighton scientist, have been working on the development of a potentially life-saving treatment for one of the most malignant and aggressive brain tumours.

Glioblastoma multiforme (GBM) accounts for half of all brain tumours and has a high recurrence rate, usually resulting in aggressive surgery plus chemotherapy and radiotherapy.

Now, researchers have proposed a new treatment using nanoparticles which deliver chemotherapeutic drugs and therapeutic antibodies directly to the cancer. In vitro experiments showed this can be significantly more efficacious and has the additional benefit of avoiding invasive surgery.

More research is needed before the new therapy can be given to patients but, the researchers said, it “…has the potential to revolutionise anti-cancer treatment by combining different killing strategies”.

The research project ‘GLIOMA’ was undertaken by Dr Sreejith Raveendran with the support of the Marie Skłodowska-Curie (MSC) programme, and is published by the European Commission’s CORDIS information service.

The project was coordinated by Dr Irina Savina, from the University of Brighton’s Biomaterials and Drug Delivery Research and Enterprise Group.

Dr Irina SavinaDr Savina, Senior Lecturer in the School of Pharmacy and Biomolecular Science, said: “Administration of combinatorial therapies that include chemotherapeutic agents and immunogens is the way forward for cancer treatment; not only do you kill cancer cells, but you also establish durable immunological memory to prevent tumour recurrence.” To read the full CORDIS article on the project (Grant 749403) click here, and for more information on Dr Savina, see her professional profile.

Laura Ruby • April 7, 2020


Previous Post

Next Post

Leave a Reply

Your email address will not be published / Required fields are marked *

Subscribe By Email

Get a weekly email of all new posts.

This form is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Skip to toolbar